Literature DB >> 22272498

Why oncologists should refer patients earlier for hospice care.

Charles F von Gunten1, Stephen Lutz, Frank D Ferris.   

Abstract

The majority of patients with advanced malignancy die with a predictable disease trajectory. Increasing use of chemotherapy and radiotherapy near the end of life has not changed that trajectory. For adults with advanced solid tumors, the period from becoming symptomatic to death of the patient is 4 to 6 weeks. Poor performance status is still the most important prognostic factor, among others that have been described. The data are now in; hospice care is the best standard of care for cancer patients, it is not an alternative to standard care. Payers for high-quality cancer care will expect referral with an interval of care--generally on the order of 4 to 6 weeks of enrollment--as a measure of quality cancer care given by the oncologist. In this article, prognostic data are summarized and a suggested approach for discussing hospice enrollment with patients is presented.

Entities:  

Mesh:

Year:  2011        PMID: 22272498

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  3 in total

1.  Is It the Difference a Day Makes? Bereaved Caregivers' Perceptions of Short Hospice Enrollment.

Authors:  Deborah P Waldrop; Mary Ann Meeker; Jean S Kutner
Journal:  J Pain Symptom Manage       Date:  2016-05-24       Impact factor: 3.612

2.  Radiation therapy in the last month of life.

Authors:  Anand Patel; Jacquelyn Dunmore-Griffith; Stephen Lutz; Peter A S Johnstone
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-16

3.  The association of race with timeliness of care and survival among Veterans Affairs health care system patients with late-stage non-small cell lung cancer.

Authors:  Leah L Zullig; William R Carpenter; Dawn T Provenzale; Morris Weinberger; Bryce B Reeve; Christina D Williams; George L Jackson
Journal:  Cancer Manag Res       Date:  2013-07-24       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.